All Stories

  1. Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging – Commentary

    Article • Multiple Sclerosis Journal, July 2018, SAGE Publications

    Dr Jaume Sastre-Garriga

  2. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report

    Article • Multiple Sclerosis Journal, February 2018, SAGE Publications

    Dr Jaume Sastre-Garriga

  3. “Brain reserve” and “cognitive reserve” should always be taken into account when studying neurodegeneration – NO

    Article • Multiple Sclerosis Journal, January 2018, SAGE Publications

    Dr Jaume Sastre-Garriga

  4. Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations

    Article • Multiple Sclerosis Journal, April 2017, SAGE Publications

    Dr Jaume Sastre-Garriga

  5. Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images

    Article • American Journal of Neuroradiology, November 2016, American Society of Neuroradiology (ASNR)

    Dr Jaume Sastre-Garriga

  6. Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI

    Article • European Radiology, July 2016, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  7. Multiple sclerosis: Dimethyl fumarate is coming of age

    Article • Nature Reviews Neurology, July 2016, Nature

    Dr Jaume Sastre-Garriga

  8. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

    Article • Multiple Sclerosis Journal, July 2016, SAGE Publications

    Dr Jaume Sastre-Garriga

  9. Grey matter atrophy is associated with disability increase in natalizumab-treated patients

    Article • Multiple Sclerosis Journal, July 2016, SAGE Publications

    Dr Jaume Sastre-Garriga

  10. Precision medicine in multiple sclerosis

    Article • Current Opinion in Neurology, June 2016, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  11. An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy

    Article • Multiple Sclerosis Journal, May 2016, SAGE Publications

    Dr Jaume Sastre-Garriga

  12. Leptomeningeal enhancement in Susac’s syndrome and multiple sclerosis: Time to expect the unexpected?

    Article • Multiple Sclerosis Journal, April 2016, SAGE Publications

    Dr Jaume Sastre-Garriga

  13. Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics

    Article • Journal of Neuroimaging, March 2016, Wiley

    Dr Jaume Sastre-Garriga

  14. Longitudinal fMRI studies: Exploring brain plasticity and repair in MS

    Article • Multiple Sclerosis Journal, March 2016, SAGE Publications

    Dr Jaume Sastre-Garriga

  15. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

    Article • The Lancet Neurology, March 2016, Elsevier

    Dr Jaume Sastre-Garriga

  16. Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load

    Article • Neuroradiology, February 2016, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  17. Highlights from the 31st ECTRIMS congress – Barcelona 2015

    Article • Multiple Sclerosis Journal, December 2015, SAGE Publications

    Dr Jaume Sastre-Garriga

  18. Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

    Article • Multiple Sclerosis Journal, December 2015, SAGE Publications

    Dr Jaume Sastre-Garriga

  19. Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe

    Article • Journal of the Neurological Sciences, December 2015, Elsevier

    Dr Jaume Sastre-Garriga

  20. Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis

    Article • American Journal of Neuroradiology, October 2015, American Society of Neuroradiology (ASNR)

    Dr Jaume Sastre-Garriga

  21. Predictive value of early brain atrophy on response in patients treated with interferon β

    Article • Neurology Neuroimmunology & Neuroinflammation, July 2015, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  22. Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy

    Article • Deutsche Zeitschrift für Nervenheilkunde, June 2015, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  23. Significant clinical worsening after natalizumab withdrawal: Predictive factors

    Article • Multiple Sclerosis Journal, May 2015, SAGE Publications

    Dr Jaume Sastre-Garriga

  24. Brain atrophy in natalizumab-treated patients: A 3-year follow-up

    Article • Multiple Sclerosis Journal, May 2015, SAGE Publications

    Dr Jaume Sastre-Garriga

  25. Defining high, medium and low impact prognostic factors for developing multiple sclerosis

    Article • Brain, April 2015, Oxford University Press (OUP)

    Dr Jaume Sastre-Garriga

  26. Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling

    Article • NeuroImage Clinical, January 2015, Elsevier

    Dr Jaume Sastre-Garriga

  27. Adherence in multiple sclerosis (ADAMS): Classification, relevance, and research needs. A meeting report

    Article • Multiple Sclerosis Journal, November 2014, SAGE Publications

    Dr Jaume Sastre-Garriga

  28. Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

    Article • Multiple Sclerosis Journal, October 2014, SAGE Publications

    Dr Jaume Sastre-Garriga

  29. Diagnosis and trials of clinically isolated syndrome

    Article • The Lancet Neurology, October 2014, Elsevier

    Dr Jaume Sastre-Garriga

  30. Predictive markers of disease evolution after a CIS in everyday practice

    Article • Journal of the Neurological Sciences, August 2014, Elsevier

    Dr Jaume Sastre-Garriga

  31. Multiple sclerosis registries in Europe – results of a systematic survey

    Article • Multiple Sclerosis Journal, April 2014, SAGE Publications

    Dr Jaume Sastre-Garriga

  32. One step forward in the quest for evidence of the efficacy of cognitive rehabilitation in multiple sclerosis

    Article • Multiple Sclerosis Journal, January 2014, SAGE Publications

    Dr Jaume Sastre-Garriga

  33. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study

    Article • Journal of Neuroinflammation, January 2014, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  34. Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment

    Article • PLoS ONE, December 2013, PLOS

    Dr Jaume Sastre-Garriga

  35. Clinical impact of early brain atrophy in clinically isolated syndromes

    Article • Multiple Sclerosis Journal, December 2013, SAGE Publications

    Dr Jaume Sastre-Garriga

  36. Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis

    Article • Disability and Rehabilitation, August 2013, Taylor & Francis

    Dr Jaume Sastre-Garriga

  37. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

    Article • Multiple Sclerosis Journal, August 2013, SAGE Publications

    Dr Jaume Sastre-Garriga

  38. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration

    Article • Multiple Sclerosis Journal, June 2013, SAGE Publications

    Dr Jaume Sastre-Garriga

  39. Localized grey matter atrophy in multiple sclerosis: A meta-analysis of voxel-based morphometry studies and associations with functional disability

    Article • Neuroscience & Biobehavioral Reviews, June 2013, Elsevier

    Professor David Mataix-Cols, Dr Jaume Sastre-Garriga

  40. Idiopathic Inflammatory Demyelinating Diseases of the Brainstem

    Article • Seminars in Ultrasound CT and MRI, April 2013, Elsevier

    Dr Jaume Sastre-Garriga

  41. Brain atrophy and lesion load predict long term disability in multiple sclerosis

    Article • Journal of Neurology Neurosurgery & Psychiatry, March 2013, BMJ

    Dr Stefan Ropele, Dr Jaume Sastre-Garriga

  42. The International Multiple Sclerosis Clinic – A Virtual Tour of Best Practice Multiple Sclerosis Nursing

    Article • European Neurological Review, January 2013, Touch Digital Media, Ltd.

    Dr Jaume Sastre-Garriga

  43. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS

    Article • Acta Neurologica Scandinavica, December 2012, Wiley

    Dr Jaume Sastre-Garriga

  44. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision

    Article • Multiple Sclerosis Journal, August 2012, SAGE Publications

    Dr Jaume Sastre-Garriga

  45. Fe de errores de «Anticuerpos monoclonales en desarrollo en esclerosis múltiple»

    Article • Neurología, June 2012, Elsevier

    Dr Jaume Sastre-Garriga

  46. Value of NMO-IgG determination at the time of presentation as CIS

    Article • Neurology, May 2012, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  47. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain

    Article • Multiple Sclerosis Journal, April 2012, SAGE Publications

    Dr Jaume Sastre-Garriga

  48. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

    Article • European Journal of Neurology, January 2012, Wiley

    Dr Jaume Sastre-Garriga

  49. Anticuerpos monoclonales en desarrollo en esclerosis múltiple

    Article • Neurología, November 2011, Elsevier

    Dr Jaume Sastre-Garriga

  50. Monoclonal antibodies in development in multiple sclerosis

    Article • Neurología (English Edition), November 2011, Elsevier

    Dr Jaume Sastre-Garriga

  51. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

    Article • Expert Review of Neurotherapeutics, May 2011, Informa Healthcare

    Dr Jaume Sastre-Garriga

  52. A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis

    Article • Multiple Sclerosis Journal, April 2011, SAGE Publications

    Dr Jaume Sastre-Garriga

  53. Using the WHOQOL-DIS to Measure Quality of Life in Persons with Physical Disabilities Caused by Neurodegenerative Disorders

    Article • Neurodegenerative Diseases, January 2011, Karger Publishers

    Dr Jaume Sastre-Garriga

  54. Multiple sclerosis: Lesion location may predict disability in multiple sclerosis

    Article • Nature Reviews Neurology, December 2010, Nature

    Dr Jaume Sastre-Garriga

  55. A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population

    Article • Neurology, November 2010, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  56. Brainstem lesions in clinically isolated syndromes

    Article • Neurology, November 2010, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  57. Development and pilot phase of a European MS register

    Article • Deutsche Zeitschrift für Nervenheilkunde, May 2010, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  58. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal

    Article • Multiple Sclerosis Journal, December 2009, SAGE Publications

    Dr Jaume Sastre-Garriga

  59. Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS

    Article • Deutsche Zeitschrift für Nervenheilkunde, November 2009, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  60. Plasma levels of 15d-PGJ2are not altered in multiple sclerosis

    Article • European Journal of Neurology, November 2009, Wiley

    Dr Jaume Sastre-Garriga, Prof Maria Angeles Moro

  61. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

    Article • Multiple Sclerosis Journal, October 2009, SAGE Publications

    Dr Jaume Sastre-Garriga

  62. Measures in the first year of therapy predict the response to interferon β in MS

    Article • Multiple Sclerosis Journal, July 2009, SAGE Publications

    Dr Jaume Sastre-Garriga

  63. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis

    Article • Journal of the Neurological Sciences, July 2009, Elsevier

    Dr Jaume Sastre-Garriga

  64. A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis

    Article • Archives of Neurology, May 2009, American Medical Association (AMA)

    Dr Jaume Sastre-Garriga

  65. Role of MRI criteria and OB for diagnosing multiple sclerosis in patients presenting with clinically isolated syndromes

    Article • Multiple Sclerosis Journal, March 2009, SAGE Publications

    Dr Jaume Sastre-Garriga

  66. New treatment measurements for treatment effects on relapses and progression

    Article • Journal of the Neurological Sciences, November 2008, Elsevier

    Dr Jaume Sastre-Garriga

  67. Mapping the brain pathways of declarative verbal memory: Evidence from white matter lesions in the living human brain

    Article • NeuroImage, September 2008, Elsevier

    Dr Jaume Sastre-Garriga

  68. Research Highlights

    Article • Therapy, September 2008, Future Medicine

    Dr Jaume Sastre-Garriga

  69. Very early scans for demonstrating dissemination in time in multiple sclerosis

    Article • Multiple Sclerosis Journal, June 2008, SAGE Publications

    Dr Jaume Sastre-Garriga

  70. Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study

    Article • Annals of Neurology, June 2008, Wiley

    Dr Jaume Sastre-Garriga

  71. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis

    Article • Multiple Sclerosis Journal, January 2008, SAGE Publications

    Dr Jaume Sastre-Garriga

  72. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2007, BMJ

    Dr Jaume Sastre-Garriga

  73. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

    Article • Neurology, September 2007, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  74. Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis

    Article • Archives of Neurology, March 2007, American Medical Association (AMA)

    Dr Jaume Sastre-Garriga

  75. Baseline MRI predicts future attacks and disability in clinically isolated syndromes

    Article • Neurology, September 2006, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  76. Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients

    Article • Multiple Sclerosis Journal, August 2006, SAGE Publications

    Dr Jaume Sastre-Garriga

  77. Regional Gray Matter Atrophy in Early Primary Progressive Multiple Sclerosis

    Article • Archives of Neurology, August 2006, American Medical Association (AMA)

    Dr Jaume Sastre-Garriga

  78. Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis

    Article • Clinical Neurology and Neurosurgery, July 2006, Elsevier

    Dr Jaume Sastre-Garriga

  79. Metabolite changes in early relapsing–remitting multiple sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, November 2005, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  80. Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data

    Article • Neurology, August 2005, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  81. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study

    Article • Brain, June 2005, Oxford University Press (OUP)

    Dr Jaume Sastre-Garriga

  82. Metabolite Changes in Normal-Appearing Gray and White Matter Are Linked With Disability in Early Primary Progressive Multiple Sclerosis

    Article • Archives of Neurology, April 2005, American Medical Association (AMA)

    Dr Jaume Sastre-Garriga

  83. Gray and white matter volume changes in early RRMS: A 2-year longitudinal study

    Article • Neurology, March 2005, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  84. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis

    Article • Multiple Sclerosis Journal, August 2004, SAGE Publications

    Dr Jaume Sastre-Garriga

  85. Decreased MMP-9 production in primary progressive multiple sclerosis patients

    Article • Multiple Sclerosis Journal, August 2004, SAGE Publications

    Dr Jaume Sastre-Garriga

  86. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis

    Article • NeuroImage, May 2004, Elsevier

    Dr Jaume Sastre-Garriga

  87. Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes

    Article • Archives of Neurology, February 2004, American Medical Association (AMA)

    Dr Jaume Sastre-Garriga

  88. APS and the brain

    Article • Lupus, December 2003, SAGE Publications

    Dr Jaume Sastre-Garriga

  89. Clinically definite multiple sclerosis after radiological Schilder-like onset

    Article • Deutsche Zeitschrift für Nervenheilkunde, July 2003, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  90. Unconventional therapy in multiple sclerosis

    Article • Multiple Sclerosis Journal, June 2003, SAGE Publications

    Dr Jaume Sastre-Garriga

  91. Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis

    Article • Multiple Sclerosis Journal, June 2003, SAGE Publications

    Dr Jaume Sastre-Garriga

  92. C onversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fl uid and neurophysiological findings

    Article • Multiple Sclerosis Journal, February 2003, SAGE Publications

    Dr Jaume Sastre-Garriga

  93. New diagnostic criteria for multiple sclerosis: Application in first demyelinating episode

    Article • Neurology, January 2003, Wolters Kluwer Health

    Dr Jaume Sastre-Garriga

  94. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β

    Article • Journal of Neuroimmunology, September 2002, Elsevier

    Dr Jaume Sastre-Garriga

  95. Response to botulinum toxin in a case of rigid spine syndrome

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2001, BMJ

    Dr Jaume Sastre-Garriga

  96. Polyglandular autoimmune syndrome type II and multiple sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, April 2001, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  97. Transient Ischaemic Attack: A Common Initial Manifestation of Cardiac Myxomas

    Article • European Neurology, April 2001, Karger Publishers

    Dr Jaume Sastre-Garriga

  98. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis

    Article • Annals of Neurology, March 2001, Wiley

    Dr Jaume Sastre-Garriga

  99. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis

    Article • Annals of Neurology, March 2001, Wiley

    Dr Jaume Sastre-Garriga

  100. Lower motor neuron disease in a HIV-2 infected woman

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2000, Springer Science + Business Media

    Dr Jaume Sastre-Garriga

  101. Mitral papillary fibroelastoma as a cause of cardiogenic embolic stroke: report of two cases and review of the literature

    Article • European Journal of Neurology, July 2000, Wiley

    Dr Jaume Sastre-Garriga

  102. Oftalmoplejía bilateral aguda con elevación de anticuerpos anti-GQ1b

    Article • Medicina Clínica, January 2000, Elsevier

    Dr Jaume Sastre-Garriga

  103. Daclizumab to treat multiple sclerosis

    Article • Cambridge University Press

    Dr Jaume Sastre-Garriga